La cadena de opciones muestra datos clave de las opciones de acciones de Moleculin Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Moleculin Biotech..

Moleculin Biotech (NASDAQ:MBRX) Bolsa, Cadena de Opciones

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

ABNB

BLAC

BSLK

CNSP

FFIE

INFA

JRSH

MBRX

MYNA

PCLA

SLSR

STAI

STVN

VRPX

ZCAR

Airbnb supera expectativas de ingresos y sus acciones suben un 13,9% en premercado. Descubre qué otros valores están destacando hoy.

Acciones de Airbnb (ABNB) suben alrededor del 14%; 20 acciones que se mueven en el premercado de EE.UU.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APPS

AVGR

BBAI

COHR

DGLY

FORM

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SLXN

SWKS

Coherent sorprende con sus resultados trimestrales y dispara sus acciones un 15,5%. ¿Qué otras empresas se mueven en el premercado de EE.UU.?

Acciones de Coherent (COHR) se disparan un 15%; 20 acciones que se mueven en el premercado de EE.UU.

Moleculin Biotech Inc

Hess's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) short percent of float has risen 13.92% since its last report. The company recently reported that it has 8.68 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Hess Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747249257_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hess has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hess's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Hess's peer group average for short interest as a percentage of float is 7.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Hess's Recent Short Interest

During the last three months, 5 analysts shared their evaluations of Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $44.2, a high estimate of $48.00, and a low estimate of $40.00. Surpassing the previous average price target of $43.00, the current average has increased by 2.79%.
<img src="https://www.benzinga.com/files/images/story/2025/1747249252_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Aramark's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karl Green</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>James Ainley</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$48.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Aramark. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aramark compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Aramark's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Aramark's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARMK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Aramark analyst ratings.</a>
<h2>Get to Know Aramark Better</h2>
Aramark provides food, facilities, and uniform services to a variety of clients and institutions. The majority of company revenue comes from its North American food and support services segment. Smaller but substantial segments include food and support services international, food and support services united states and uniform and career apparel. The food and support services segments provide food for school districts; colleges; healthcare facilities; correctional institutions; and business, sports, and entertainment venues. The uniform segment rents, delivers, cleans, and maintains work clothes and ancillary items like towels and mats to customers in North America and Japan. The company has hundreds of service locations and distribution centers across the United States and Canada.
<h3>Understanding the Numbers: Aramark's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Aramark displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.89%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Aramark's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.03%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.47%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.27.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ARMK

Assessing Aramark: Insights From 5 Financial Analysts

Archer-Daniels-Midland's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) short percent of float has fallen 5.44% since its last report. The company recently reported that it has 13.79 million shares sold short, which is 3.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Archer-Daniels-Midland Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747249251_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Archer-Daniels-Midland has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Archer-Daniels-Midland's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Archer-Daniels-Midland's peer group average for short interest as a percentage of float is 3.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Archer-Daniels-Midland?

Post Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) short percent of float has fallen 10.02% since its last report. The company recently reported that it has 2.63 million shares sold short, which is 5.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Post Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747249246_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Post Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Post Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Post Holdings's peer group average for short interest as a percentage of float is 6.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

POST

Looking Into Post Holdings's Recent Short Interest

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $784.56, a high estimate of $1000.00, and a low estimate of $547.00. Highlighting a 10.35% decrease, the current average has fallen from the previous average price target of $875.13. 
<img src="https://www.benzinga.com/files/images/story/2025/1747249241_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$700.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$810.00</td>
<td>$940.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$940.00</td>
<td>$975.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$804.00</td>
<td>$917.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$943.00</td>
<td>$1051.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$700.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$800.00</td>
<td>$865.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$633.00</td>
<td>$768.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$587.00</td>
<td>$652.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$652.00</td>
<td>$759.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$975.00</td>
<td>$1004.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$850.00</td>
<td>$1152.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$695.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$547.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$917.00</td>
<td>$1019.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$1100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regeneron Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Regeneron Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Regeneron Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>Discovering Regeneron Pharmaceuticals: A Closer Look</h2>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
<h3>A Deep Dive into Regeneron Pharmaceuticals's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Regeneron Pharmaceuticals's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.7%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Regeneron Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 26.7%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.75%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 2.15%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REGN

Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock

During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $58.2, a high estimate of $77.00, and a low estimate of $30.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1747249230_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Capricor Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Capricor Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Capricor Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Capricor Therapeutics: A Closer Look</h2>
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
<h3>Capricor Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Capricor Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -7.92%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -63.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Capricor Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.4%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

Forecasting The Future: 5 Analyst Projections For Capricor Therapeutics

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.22, a high estimate of $3.00, and a low estimate of $1.50. Highlighting a 22.92% decrease, the current average has fallen from the previous average price target of $2.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1747249216_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive 8x8. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Nichols</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.70</td>
<td>$3.30</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.90</td>
<td>$2.60</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 8x8. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of 8x8 compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for 8x8's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of 8x8's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EGHT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on 8x8 analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About 8x8</h2>
8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. The Company also generates revenue from sales of hardware and professional services, which are complementary to the delivery of its integrated technology platform.. Geographically, it derives a majority of revenue from the United States.
<h3>8x8's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Challenges: 8x8's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -1.17%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: 8x8's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.69%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): 8x8's ROE stands out, surpassing industry averages. With an impressive ROE of 2.71%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): 8x8's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.42%, the company showcases efficient use of assets and strong financial health.
Debt Management: 8x8's debt-to-equity ratio stands notably higher than the industry average, reaching 3.77. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EGHT

Forecasting The Future: 5 Analyst Projections For 8x8

WIIM

ABBV

AbbVie shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $210 to $205.

Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) on Tuesday reported its first quarter of 2025 adjusted earnings of 62 cents per share, compared to 17 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 36 cents</a>.
The cancer-focused company reported quarterly sales of $555.45 million, beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45410642/exelixis-crushes-q1-earnings-estimates-with-strong-cabometyx-sales-raises-2025-revenue-guidance" rel="noreferrer noopener">consensus of $498.18 million</a>.
Total revenues included net product revenues of&nbsp;$513.3 million, compared to&nbsp;$378.5 million&nbsp;for the comparable period in 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44499265/fda-approves-exelixis-lead-cancer-drug-cabometyx-for-expanded-use-in-neuroendocrine-tumors" rel="noreferrer noopener">FDA Approves Exelixis&#8217; Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors</a>
Guidance: &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by $100 million,&#8221; <a href="https://www.benzinga.com/general/biotech/25/05/45410642/exelixis-crushes-q1-earnings-estimates-with-strong-cabometyx-sales-raises-2025-revenue-guidance">said</a> Michael M. Morrissey, president and CEO of Exelixis.
The company raised fiscal 2025 sales guidance from $2.15 billion-$2.25 billion to $2.25 billion-$2.35 billion, versus the consensus of $2.25 billion.
Stifel writes, &#8220;We note the NET launch should prove a tailwind to FY25 topline growth and command an additional guidance raise above the $100 million announced today. We continue to believe 2H25 zanzalintinib clinical catalysts will prove a more significant driver of investor enthusiasm&#8230;&#8221;
Analyst Stephen Willey highlights, &#8220;Management noted there is a significant overlap between target NET physicians and legacy Cabometyx prescribers and believes Cabometyx is well positioned to capture a significant portion of the small molecule NET market, which, per management, is estimated at $1B in FY25.&#8221;
Willey maintains the Hold rating for Exelixis and raises the price <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $36 to $38</a>.
Stifel updated fiscal 2025, 2026 and 2027 Cabometyx sales estimates, primarily reflecting continued first-line RCC share gains and an accelerated NET launch trajectory. The analyst updates sales estimates to $2.141 billion, $2.439 billion and $2.712 billion versus $2.062 billion, $2.35 billion, and $2.54 billion, respectively, expected previously.
EXEL Price Action: Exelixis stock was up 20% at $44.3 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45411148/taiwan-semiconductor-commits-15-billion-to-chip-expansion-approves-dividend-amid-rising-global-demand" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Commits $15 Billion To Chip Expansion, Approves Dividend</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Earnings

Guidance

Health Care

General

EXEL

Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat

Arcos Dorados Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) shares are trading lower on Wednesday after the company <a href="https://www.benzinga.com/pressreleases/25/05/b45402722/arcos-dorados-reports-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">reported first-quarter results</a>. Arcos Dorados Holdings is the master franchise of the fast food restaurant chain McDonald&#8217;s in 20 countries and territories across Latin America and the Caribbean.
Arcos reported earnings per share of 7 cents, missing the Street view of 13 cents. Quarterly sales of $1.08 billion (flat year-over-year) outpaced the analyst <a href="https://www.benzinga.com/earnings">consensus estimate of $1.05 billion</a>.
Total revenues grew 14.1% in constant currency, supported by 11.1% higher systemwide comparable sales.
Digital sales rose 6.3% in the period, helped by close to 19 million monthly average users of the mobile app. Digital channels generated almost 60% of systemwide sales in the quarter.
Also Read:<a target="_blank" href="https://www.benzinga.com/general/restaurants/25/05/45369152/mcdonalds-launches-massive-summer-hiring-drive-for-375000-workers-amid-us-expansion-plans-and-slumping-sales" rel="noreferrer noopener"> McDonald&#8217;s Launches Massive Summer Hiring Drive For 375,000 Workers Amid US Expansion Plans And Slumping Sales</a>
Adjusted EBITDA for the quarter slumped 16.2% on a year-over-year basis to $91.3 million in the quarter under review. Adjusted EBITDA margin contracted to 8.5% from 10.1%.
The Loyalty Program reached 18.8 million registered members at the end of the quarter, supporting increased frequency and higher average check in available markets.
Consolidated profitability declined compared to last year due mainly to weaker local currencies and margin pressures in Brazil.
The net income margin attributable to the company was 1.3%, or 130 basis points lower, versus the first quarter of 2024.&nbsp;
&#8220;Even as consumers pulled back on eating out of home during the quarter, off-premise channels remained resilient, generating about 43% of total systemwide sales in the quarter,&#8221; said CEO Marcelo Rabach.
Arcos Dorados added 12 new EOTF restaurants to the company&#8217;s footprint, including 10 free-standing units, in the first quarter of 2025.
The company said it plans to accelerate the pace of openings as the year progresses to meet its full-year guidance of 90 to 100 new restaurants.
Price Action: ARCO shares are trading lower by 6.13% to $7.660 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45408452/stock-of-the-day-palantir-breaks-out-sell-news-rally" target="_blank" rel="noreferrer noopener">Stock Of The Day: Palantir Breaks Out As Classic &#8216;Sell the News&#8217; Sets Up Rally</a></li>
</ul>
Image by sombat muycheen via Shutterstock

Equities

Restaurants

ARCO

Why Is McDonald's Franchisee Arcos Dorados Stock Falling On Wednesday?

H.C. Wainwright &amp; Co. analyst Sameer Joshi trimmed the price forecast for Blink Charging Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) from $8 to $5 <a href="https://www.benzinga.com/quote/BLNK/analyst-ratings" target="_blank" rel="noreferrer noopener">while keeping a Buy rating</a>.
On May 12, Blink reported first-quarter losses of 18 cents per share, which missed the analyst consensus estimate of losses of 14 cents. Revenue came in at $20.75 million, which missed the <a href="https://www.benzinga.com/news/earnings/25/05/45361168/blink-charging-stock-fizzles-after-worse-than-expected-q1-results" target="_blank" rel="noreferrer noopener">Street estimate of $27.6 million</a>.
The analyst&#8217;s bearish stance reflects ongoing weakness in product sales, which declined 69.5% year-over-year to $8.4 million in the first quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44378699/blink-expands-in-mexico-with-porsche-ev-charging-deal-details" rel="noreferrer noopener">Blink Expands In Mexico With Porsche EV Charging Deal: Details</a>
The analyst notes that management has intensified its focus on a few core strategies, including customer-centric business models, expanding DC Fast Charging offerings, and cultivating recurring revenue streams.
For 2025, the company expects a sequential increase in revenues generated from its services, alongside a robust revenue performance in the latter half <a href="https://www.benzinga.com/calendars/guidance">of 2025, adds the analyst</a>.
Joshi anticipates that Blink&#8217;s strategic emphasis on increasing its portfolio of owned DC Fast Charging infrastructure to lead to higher revenues from services, as well as an overall increase in total revenues in the upcoming quarters.
Furthermore, the analyst says that the company remains on track to pursue the monetization of its ride-sharing business in 2025.
Nevertheless, Joshi remains cautious as the company navigates the current challenges in the EV charging industry and the uncertain macroeconomic and geopolitical landscape.
Consequently, the analyst revised the 2025 revenue estimates to $95.1 million, down from the previous $131.1 million, and adjusted the EBITDA estimate to a loss of $24.7 million (vs. a $3.2 million loss earlier).
Price Action: BLNK shares are down 1.97% at $0.7618 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/44251890" target="_blank" rel="noreferrer noopener">FuelCell Energy Reports&nbsp;Q1&nbsp;Miss, Highlights Lower Losses And Positive Momentum From Global Restructuring Plan</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

Small Cap

BLNK

Blink's Bumpy Road: Analyst Flags Sluggish Product Sales As Key Concern, Trims Estimates

JP Morgan analyst Bill Peterson reiterated a Neutral rating on Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) but <a target="_blank" href="https://www.benzinga.com/quote/PLUG/analyst-ratings" rel="noreferrer noopener">has withdrawn the price forecast</a>.
On May 12, 2025, the company reported first-quarter revenue of $133.67 million, beating analyst&nbsp;estimates of $132.16 million and a loss of 21 cents per share, missing analyst estimates for <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45361043/plug-power-q1-earnings-revenue-beats-estimates-driven-by-575-growth-in-electrolyzer-sales-eps-falls-short-company-highlights-real-progress-toward-profitability" rel="noreferrer noopener">a loss of 19 cents per share</a>.
Plug Power guided for second-quarter revenue in the range of $140 million to $180 million, versus estimates of $132.16 million, signaling <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45387898/plug-power-stock-is-tumbling-tuesday-whats-going-on" rel="noreferrer noopener">confidence in continued demand growth</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/05/45311929/plug-power-partners-up-with-basf-will-use-german-companys-purification-tech-to-liquify-hydrogen" rel="noreferrer noopener">Plug Power Partners Up With BASF: Will Use German Company&#8217;s Purification Tech To Liquify Hydrogen</a>
The analyst adjusted its second-quarter revenue estimates towards the lower end of the company&#8217;s guidance range at $150 million (down from $156 million prior).
Peterson has also slightly reduced the electrolyzer growth projections for the year, anticipating potential deal delays into 2026.
Consequently, the analyst lowered the full-year revenue estimate to $729 million (from $756 million previously).
The analyst also factored in Plug Power&#8217;s need to raise an additional $100 million to $200 million to bridge the funding gap required for the initial drawdown of its Department of Energy (DOE) loan, which may occur later this year or in early 2026.
Overall, the analyst says that Plug Power has significant potential for future growth through expansion into new markets, geographies, and the green hydrogen sector.
However, the company currently faces near-term challenges related to liquidity, margin improvement, and the availability of hydrogen, which is impacting its current outlook.
Investors can gain exposure to the stock via Global X Hydrogen ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYDR#NASDAQ">HYDR</a>).
Price Action: PLUG shares are down 3.91% at $0.78 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45183625/benzinga-bulls-and-bears-lilly-microsoft-starbucks-and-markets-fully-recover-tariff-chaos-losses" target="_blank" rel="noreferrer noopener">Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Losses</a></li>
</ul>
Image via Shutterstock

HYDR

PLUG

JP Morgan Signals Caution On Plug Power's Near-Term Challenges, Withdraws Price Forecast

<a href="https://www.adweek.com/convergent-tv/netflix-ad-tier-94-million-monthly-active-users/">https://www.adweek.com/convergent-tv/netflix-ad-tier-94-million-monthly-active-users/</a>

NFLX

'Netflix Ad Tier Hits 94 Million Global Monthly Active Users'- Adweek

U.S. tech stocks extended their weekly rally into Wednesday's session, lifted by renewed investor appetite for risk following a breakthrough in early-week U.S.-China trade negotiations. This reignited hopes for a more <a href="https://www.benzinga.com/topic/tariffs">stable global trade outlook. </a>
The Nasdaq 100 rose 0.5% by midday in New York, reaching levels last seen in late February. Heavyweight chipmakers led the rally, as Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) surged 4% and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) jumped 5%.
Traders welcomed mounting expectations of large-scale investments from Gulf nations into U.S. tech and semiconductor sectors, as President Donald Trump secured new economic agreements with <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Middle Eastern countries</a>, including Saudi Arabia and Syria.
While the Nasdaq marched higher, the S&amp;P 500 stalled and both the Dow Jones Industrial Average and Russell 2000 slipped slightly, indicating a more selective rally focused on high-growth sectors.
Clean energy and solar stocks outperformed again, building on strong Tuesday gains. Investors cheered a less-severe-than-expected revision to clean energy tax credits in the latest Republican tax proposal.
The commodity space told a different story, with gold prices dropping nearly 2%, breaking below the $3,200 per ounce mark for the first time in over a month. 
The yellow metal is now tracking its worst weekly performance since November 2024, with two trading sessions still left this week.
Investors appear to be rotating out of safe-haven assets, as appetite for equities and riskier plays returns on global trade optimism. 
Rising Treasury yields also weighed on broader market sentiment. The yield on the 2-year Treasury note broke above 4%, hitting its highest level in more than two months. Meanwhile, the 30-year bond yield rose 5 basis points to 4.97%, drawing closer to the psychologically important 5% mark—a level often associated with tightening financial conditions and pressure on long-duration assets.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,273.30</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,891.20</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,075.32</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,089.17</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $586.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.3% to $420.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $517.40.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.6% lower to $207.35.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.8%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Israeli retail broker Etoro Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) made his debut on the Nasdaq 100 index. Shares were up 26%.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rallied for a second straight session, jumping 18% to $45.99 on Monday after a 16% gain the previous day.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) advanced 1.9% after securing a major deal with Qatar Airways, which agreed to purchase up to 210 Boeing 787 Dreamliner and 777X aircraft in a transaction valued at $96 billion.</li>
<li>Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) soared 20% after the biotech firm posted first-quarter earnings and revenue that topped Wall Street estimates.</li>
<li>Stocks slated to report earnings after the close include Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Copart Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) and Steris plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>). </li>
</ul>
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45414023/magnificent-seven-add-36-trillion-since-april-lows-is-this-rally-just-beginning">Magnificent Seven Add $3.6 Trillion Since April Lows: Is This Rally Just Beginning?</a></li>
</ul>
Image: Shutterstock

Government

Large Cap

Regulations

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

CPRT

CSCO

SPDR Dow Jones Industrial Average ETF Trust

ETOR

NVDA

SMCI

Select Sector SPDR-Consumer Discretionary

Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?

LEGN

Legend Biotech shares are trading lower following Q1 reported financial results. Additionally, Truist Securities cut their price target on the stock from $88 to $71.

As co-founder of Lobster Boys LLC and a fourth-generation lobsterman, Justin Maderia has seen firsthand how global trade tensions <a href="https://www.benzinga.com/topic/economy">ripple through local economies</a>.
With the U.S. seafood market generating over $31 billion annually—and relying on Canada for more than two-thirds of its imports—tariffs and shifting trade policies are a critical concern.
The erratic nature of the trade situation doesn&#8217;t help, either. In recent weeks, President Donald Trump threatened exorbitant tariffs on China, 145% on April 10, only to slash them to <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">30% a month later</a>. Whatever ends up sticking, Maderia hopes there&#8217;s a chance to build a more resilient, transparent, and self-sufficient seafood industry.
Maderia, who launched Lobster Boys — stylized as Lobsterboys — with his brother, Travis, shares his insights on the evolving U.S.-Canada-China seafood trade, the hidden upsides of tariff pressure, and how their company navigates change while staying true to its roots. The following has been edited for clarity and conciseness.
See Also: <a href="https://www.benzinga.com/general/restaurants/25/04/45021992/us-restaurants-face-growth-hurdles-as-macro-headwinds-mount-says-analyst">US Restaurants Face Growth Hurdles As Macro Headwinds Mount, Says Analyst</a>
<h2 class="wp-block-heading">BZ: What was wrong with the fishing industry before and what are some of the different trade dynamics that have opened up?</h2>
Maderia: The fishing industry has long been a battleground of geopolitics, shrouded in fog—middlemen, opaque pricing, and zero traceability. Recent shifts, like the rollback of U.S.-China tariffs, aren't a return to the old ways; they're a wake-up call. Trade flows are recalibrating, and at Lobsterboys, we see a golden opportunity in the chaos. Disruptions expose the cracks in traditional supply chains—fragile, bloated, and unreliable.
As China's market reopens, big exporters are learning they can't bet everything on one buyer. Lobsterboys is built differently, sourcing directly from fishermen, championing full transparency, and delivering quality. This is our moment to seize domestic partnerships directly with chefs and home cooks and redefine what seafood can be.
<h2 class="wp-block-heading">How has Lobsterboys been affected by the on-again-off-again tariffs?</h2>
Tariffs always grab headlines, but what they really do is expose the deeper problems in our food system. In seafood, we've been relying on bloated, opaque supply chains for decades—layers of brokers, exporters, and overseas buyers that disconnect the people who catch the food from the people who eat it. When something like a tariff hits, that fragile system starts to crack.
For us, the disruption actually highlighted the value of a different approach—one that's more local, more nimble, and more direct. We buy straight from trusted fishermen in both the U.S. and Canada and sell directly to North American consumers. So while others were scrambling to adjust, our model stayed intact.
There's also a seasonal shift happening: Spring marks the beginning of peak lobster season in many key fisheries. That increase in supply typically brings down prices, which softens the blow of any tariff-related cost changes. So yes, tariffs have been a headache—but they've also created space for change. They've forced the industry, and consumers, to rethink where their food comes from.
<h2 class="wp-block-heading">As for the global seafood market, will there be a surplus as trading routes from exporters change?</h2>
In the short term, yes—surpluses can pop up when exporters lose access to major markets like China. The seafood supply chain isn't always quick to adapt, especially when it's designed for volume, not flexibility. But seafood is perishable, so the market corrects fast. 
The deeper issue isn't about excess—it's about misalignment. Supply and demand often don't meet efficiently. That's where direct-to-consumer models shine. They reduce waste, shorten the time between harvest and plate, and eliminate the guesswork of where the product should go. Surplus is a symptom. The real problem is a system that wasn't built to be responsive—and that's exactly what needs to change.
<h2 class="wp-block-heading">Is the seafood industry becoming more sustainable?</h2>
It's starting to, because it has to. Consumers are asking tougher questions. They want to know where their seafood comes from, how it was caught, and whether it supports coastal communities. That's progress.
There's more use of technology now—digital catch tracking, QR codes, and third-party verification—but real sustainability goes beyond that. It's about creating a system that's accountable at every level. That means fair wages for fishermen, environmentally responsible harvests, and eliminating fraud and relabeling.
We believe sustainability and transparency go hand in hand. You can't have one without the other. Our goal is to build a seafood supply chain that actually respects the ocean, the people who work it, and the people who rely on it for food.
<h2 class="wp-block-heading">If you could talk to Trump about trade, what would you say?</h2>
We'd say: President Trump was right to shake up the status quo. For too long, our food system—and especially seafood—has depended on foreign markets and broken supply chains that left American fishermen vulnerable and American consumers disconnected.
Tariffs may have caused short-term disruption, but they've forced the industry to take a hard look at where things weren't working. That disruption created opportunity—specifically, the opportunity to bring more of the seafood supply chain back home. When we strengthen direct relationships between harvesters and consumers, we keep more value in the hands of fishermen and we make the system more resilient.
What we need now is to keep building on that foundation. That means investing in infrastructure that supports coastal economies, rewarding transparency, slashing and implementing proper regulations and ensuring fair pricing for the people who work the water. This is how we secure our food future—by standing behind fishermen and empowering consumers to know their lobster and know their lobstermen.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/04/44939726/rfk-jr-will-phase-out-artificial-food-dyes-by-end-of-2026-what-it-means-for-pepsi-coca-cola-general-mills">RFK Jr. Targets Artificial Food Dyes: What It Means For Pepsi, Coca-Cola, General Mills</a></li>
</ul>
Image: Courtesy of Lobster Boys

Topics

Success Stories

Startups

Small Business

Exclusives

Interview

Lobster Life: Sibling Entrepreneurs See Trade Turmoil As A Business Edge

<a href="https://jpmorgan.metameetings.net/events/tmc25/sessions/313136-criteo-sa/webcast?gpu_only=true&amp;kiosk=true">https://jpmorgan.metameetings.net/events/tmc25/sessions/313136-criteo-sa/webcast?gpu_only=true&amp;kiosk=true</a>

CRTO

Watching Criteo S.A.; Shares See Volume To The Upside; Company Presenting At JPM Tech Conference

<ul class="wp-block-list">
<li>President Donald Trump said he'd be "OK" with "tiny" tax hikes on the rich on Friday, but warned that the changes would likely lead to pushback from the Republican party</li>
<li>The Truth Social post follows similar remarks to Time magazine last month</li>
<li>The remarks come just before Republicans are set to present the "one big beautiful bill," a piece of legislation that will cover things like tax cuts and budgetary considerations, among other things</li>
</ul>
President Donald Trump said Friday morning that he'd be "okay" with "tiny" tax hikes for the rich, but warned Republicans they should "probably not do it."
In a post on <a href="https://truthsocial.com/@realDonaldTrump/posts/114477701321152097">Truth Social</a>, Trump wrote, "The problem with even a ‘TINY' tax increase for the RICH, which I and all others would graciously accept in order to help the lower and middle income workers, is that the Radical Left Democrat Lunatics would go around screaming, ‘Read my lips,' the fabled Quote by George Bush the Elder that is said to have cost him the Election… In any event, Republicans should probably not do it, but I'm OK if they do!!!"
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
Republicans have been struggling to come up with $1.5 trillion in budget cuts to help offset the trillions of dollars in tax cuts that have resulted from the Tax Cuts and Jobs Act, which Trump signed into law in 2017.
This is not the first time Trump has indicated that he'd support tax hikes on the rich. In an interview with <a href="https://time.com/7280114/donald-trump-2025-interview-transcript/">Time</a> magazine last month, he said, "I certainly don't mind having a tax increase… I&#8217;d be raising them on wealthy to take care of middle class. And that&#8217;s—I love, that. I actually love the concept, but I don&#8217;t want it to be used against me politically."&nbsp;
House Republicans are split on the idea of tax increases for those who make over $1 million a year. When asked by the <a href="https://www.washingtonpost.com/business/2025/05/08/trump-tax-millionaires-republicans/">Washington Post</a> how many senators would support the plan, Sen. Josh Hawley (R-MO), said, "Zero probably. Maybe one or two." The <a href="https://www.washingtonpost.com/business/2025/04/22/trump-millionaire-tax-rich-gop-vance/">Post</a> also reports that House Speaker Mike Johnson (R-LA), Sen. Dave McCormick (R-PA), and Sen. Ted Cruz (R-TX), are all vehemently opposed to the idea.&nbsp;
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Insiders told <a href="https://www.reuters.com/world/us/trump-urged-speaker-johnson-raise-top-tax-rate-source-says-2025-05-08/">Reuters</a> that Trump is pushing to raise the top tax rate from 37% to 39.6% for individuals earning $2.5 million and higher and joint filers earning $5 million or more. "This will help pay for massive middle and working-class tax cuts, and protect Medicaid," a source told the outlet.
Republicans are rushing to hammer out these details so that they can complete Trump's "one big beautiful bill" by the end of the week. &nbsp;
Some details of the bill were made public on Friday when the House Ways and Means Committee released a <a href="https://subscriber.politicopro.com/f/?id=00000196-b7a4-d69e-add7-bfaf65c00000">28-page section</a> of the proposed legislation. Included were plans for an increased child tax credit and an extended roster of lower income tax rates. A much more detailed amendment, including details of how they plan to make good on Trump's promises to end the taxation of tips and overtime pay, is expected to be revealed sometime before the House Ways and Means Committee's next meeting on Tuesday, according to <a href="https://www.politico.com/live-updates/2025/05/09/congress/ways-and-means-circulates-early-tax-bill-draft-00338251">Politico</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Trump Says He's OK With 'Tiny' Tax Hikes For The Rich, But Warns Republicans There Will Be Political Backlash

LUV stock has given up its prior gain. Southwest shares were trading higher following a report indicating the company filed for a permit for more international routes.

Hampton Roads based TowneBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOWN#NASDAQ">TOWN</a>) announced today that its Board of Directors declared its second-quarter shareholder cash dividend of $0.27 per common share payable on July 11, 2025, to shareholders of record on June 27, 2025. The quarterly common stock cash dividend of $0.27 per common share, or $1.08 per common share on an annual basis, is an 8% increase from the previous dividend rate.
The amount and declaration of future cash dividends are subject to Board of Directors' approval in addition to regulatory restrictions.

Dividends

TOWN

TowneBank Hikes Quarterly Cash Dividend From $0.25 To $0.27 Per Share

Press Releases

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Comments

Moleculin Biotech

Moleculin Biotech (MBRX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL